AxoGen, Inc. (NASDAQ:AXGN) Shares Acquired by Quest Partners LLC

Quest Partners LLC lifted its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 23,066.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,085 shares of the medical equipment provider’s stock after purchasing an additional 2,076 shares during the quarter. Quest Partners LLC’s holdings in AxoGen were worth $29,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. First Light Asset Management LLC grew its stake in shares of AxoGen by 336.6% during the 2nd quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider’s stock worth $24,211,000 after purchasing an additional 2,578,147 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of AxoGen by 2,014.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,310,811 shares of the medical equipment provider’s stock worth $9,490,000 after purchasing an additional 1,248,823 shares during the period. Divisadero Street Capital Management LP grew its stake in shares of AxoGen by 587.2% during the 2nd quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider’s stock worth $4,974,000 after purchasing an additional 587,024 shares during the period. Rice Hall James & Associates LLC grew its stake in shares of AxoGen by 26.8% during the 2nd quarter. Rice Hall James & Associates LLC now owns 194,269 shares of the medical equipment provider’s stock worth $1,407,000 after purchasing an additional 41,095 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in AxoGen by 9.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 160,892 shares of the medical equipment provider’s stock valued at $1,165,000 after acquiring an additional 13,798 shares during the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on AXGN shares. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. JMP Securities increased their price objective on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research note on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $15.00.

AxoGen Price Performance

Shares of NASDAQ AXGN opened at $13.90 on Monday. The stock has a market cap of $611.74 million, a price-to-earnings ratio of -43.44 and a beta of 1.13. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $15.90. The company’s 50-day moving average price is $13.68 and its 200 day moving average price is $10.88. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.